Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ify R Mordi

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Journal of Cardiovascular Development and Disease|April 19, 2019
Non-Invasive Imaging in Diabetic CardiomyopathyIfy R Mordi
Heart Failure Clinics|October 10, 2022
Glucose-Lowering and Metabolic Effects of SGLT2 InhibitorsIfy R Mordi, Chim C Lang
JACC. Cardiovascular Imaging|July 7, 2018
The Authors ReplyIfy R Mordi, Dana K Dawson
JACC. Cardiovascular Imaging|January 6, 2018
The Authors ReplyIfy R Mordi, Dana K Dawson
Cardiac Failure Review|June 13, 2018
Iron Therapy in Heart Failure: Ready for Primetime?Ify R Mordi, Aaron Tee, Chim C Lang
Circulation|January 28, 2020
Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial"Ify R Mordi, Mohapradeep Mohan, Chim C Lang
Current Opinion in Pharmacology|May 14, 2021
Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]Graham Rena, Ify R Mordi, Chim C Lang
Current Opinion in Pharmacology|December 3, 2020
Metformin: still the sweet spot for CV protection in diabetes?Graham Rena, Ify R Mordi, Chim C Lang
Diseases (Basel, Switzerland)|September 22, 2017
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart FailureAbbey Steggall, Ify R Mordi, Chim C Lang
Circulation|January 21, 2025
SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic GapIfy R Mordi, Rory J McCrimmon, Chim C Lang
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Journal of Cardiovascular Development and Disease|April 19, 2019
Non-Invasive Imaging in Diabetic CardiomyopathyIfy R Mordi
Heart Failure Clinics|October 10, 2022
Glucose-Lowering and Metabolic Effects of SGLT2 InhibitorsIfy R Mordi, Chim C Lang
JACC. Cardiovascular Imaging|July 7, 2018
The Authors ReplyIfy R Mordi, Dana K Dawson
JACC. Cardiovascular Imaging|January 6, 2018
The Authors ReplyIfy R Mordi, Dana K Dawson
Cardiac Failure Review|June 13, 2018
Iron Therapy in Heart Failure: Ready for Primetime?Ify R Mordi, Aaron Tee, Chim C Lang
Circulation|January 28, 2020
Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial"Ify R Mordi, Mohapradeep Mohan, Chim C Lang
Current Opinion in Pharmacology|May 14, 2021
Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]Graham Rena, Ify R Mordi, Chim C Lang
Current Opinion in Pharmacology|December 3, 2020
Metformin: still the sweet spot for CV protection in diabetes?Graham Rena, Ify R Mordi, Chim C Lang
Diseases (Basel, Switzerland)|September 22, 2017
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart FailureAbbey Steggall, Ify R Mordi, Chim C Lang
Circulation|January 21, 2025
SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic GapIfy R Mordi, Rory J McCrimmon, Chim C Lang
Pageof 7